Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: Renner, Alex, Burotto, Mauricio, Valdes, Jose Miguel, Roman, Juan Carlos, Walton-Diaz, Annerleim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273398/
https://www.ncbi.nlm.nih.gov/pubmed/34290827
http://dx.doi.org/10.1177/17562872211029779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273398/
https://www.ncbi.nlm.nih.gov/pubmed/34290827
http://dx.doi.org/10.1177/17562872211029779

Ejemplares similares